Dr. Michael Sermersheim from JWM Neurology will be speaking at the Alzheimer’s Association 2017 Education Conference on Friday, June 2nd. His presentation topic is titled “Alzheimer’s and Dementia in Down Syndrome”. Spots are still available at the conference. You can inquire and register following the information on this link.
Neurology Connection News
Join Craig E. Herrman, MD, Director of JWM Neurology Research, as he presents a brief talk on the basics of Multiple Sclerosis. This is geared toward patients and families.
- Monday, December 5th, 2016 at 6:30 pm
- 7250 Clearvista Drive Multi-Service Room (3rd floor)
- Light refreshments served
- No charge
- RSVP: 317.537.6060 or email@example.com
Neurologist Matthew G. Gentry, MD, has joined JWM Neurology. Dr. Gentry received his Medical Degree in 2011 at Indiana University School of Medicine in Indianapolis. He completed his Neurology Residency in 2015, also at IU School of Medicine, where he was Chief Resident. Dr. Gentry recently completed his Fellowship in Clinical Neurophysiology with an emphasis in EEG and Epilepsy at IU School of Medicine. He sees patients with all neurologic conditions and has special interests in the areas of Epilepsy, EEG, neuromuscular conditions and EMG.
Central Indiana Neurology (CIN) located in Anderson, Indiana has joined JWM Neurology.
Our collaborative partnership together will enable us to combine and serve a larger geographic area in Central Indiana as well as continue to better serve our patients and referring physicians. Between JWM and CIN, we now have eleven locations including offices in: Indianapolis, Carmel, Mooresville, Franklin, Kokomo, Anderson and Elwood.
JWM welcomes Central Indiana Neurology physicians, Larry Blankenship, MD, Charles Howe, MD, Christopher Rocco, MD, Caroline Stevens, DO and their staff.
Northwest Radiology and JWM Neurology, both located in Indianapolis, are partnering together to offer the first and only FDA-approved diagnostic PET-CT (Positive Emission Tomography-Computed Tomography) tracer for imaging beta-amyloid neuritic plaques in the living brain. For the first time in clinical practice, physicians are now able to utilize PET-CT scanning to see evidence of amyloid plaques (deposits in the gray matter associated with brain degeneration) when evaluating patients for Alzheimer’s disease and other causes of cognitive decline. Currently, only a neuropathological exam (performed during an autopsy) can definitively diagnose Alzheimer’s disease.[Read More]